Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03712501
Other study ID # R16-P188
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2017
Est. completion date December 30, 2018

Study information

Verified date May 2019
Source Loughborough University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The present study will investigate the effect of prior walking on postprandial metabolism and endothelial function in healthy South Asian and White European women.

Participants will complete two, 2-day trials in a random, crossover design separated by at least 3 weeks to control for the menstrual cycle phase.

On day 1, participants will either rest or complete a 60 minute walk at 60% maximal oxygen uptake. On day 2, participants will arrive at 08:00 having fasted overnight and a baseline venous blood sample and endothelial function measurement will be taken. Participants will consume a high-fat breakfast and lunch and 12 subsequent venous blood samples will be taken throughout the day at standardised intervals to measure a variety of coronary heart disease risk markers. A second endothelial function measurement will be completed 2 hours after the breakfast. Blood pressure will be measured every hour.

It is expected that the South Asian participants will have impaired metabolism and endothelial function compared to their European counterparts but the bout of exercise performed on day 1 will mitigate these responses.


Description:

South Asian individuals have a higher-than-average risk of coronary heart disease. The reasons for this are unclear, but physical inactivity and/or poor responsiveness to exercise may play a role.

Previous research from our laboratory has shown that coronary heart disease risk markers in the postprandial period are elevated in South Asian men, but acute exercise was equally, if not more, effective for reducing these risk markers in South Asian than White European men. However, the effect of acute exercise on coronary heart disease risk markers has not been examined in South Asian women.

Therefore, the purpose of the present study is to compare the effect of acute exercise on endothelial function and coronary heart disease risk markers in women of South Asian versus White European descent.

On visit 1, participants will attend the laboratory to undergo preliminary assessments and to be familiarised with the laboratory environment and study procedures. Specifically, health status, habitual physical activity, dietary habits and anthropometric data (height, weight, waist and hip circumference, body fat) will be collected. Two preliminary exercise tests will be performed as follows: 1) submaximal-incremental treadmill walking test and 2) incremental treadmill running test to exhaustion to measure maximal oxygen uptake.

On visit 2, participants will undergo a magnetic resonance imaging (MRI) scan to quantify regional body composition comprising abdominal subcutaneous adipose tissue, visceral adipose tissue, liver fat percentage, thigh intramuscular adipose tissue and thigh muscle volume.

On visits 3-6 participants will complete two, 2-day trials in a random, crossover design seperated by at least 3 weeks to control for the menstrual cycle phase. On day 1 of both trials, participants will arrive fasted at 08:00 and a baseline blood sample, blood pressure and endothelial function measurement will be taken. Participants will consume a standardised high fat breakfast at 09:00 and lunch at 13:00. At 15:30 the participants will walk for 60 minutes at 60% maximal oxygen uptake and complete a second endothelial function measurement at 16:45. Participants will leave the laboratory with a standardised evening meal to consume before 22:00. The control trial will be the same, except no exercise will be performed.

On day 2, participants will arrive at 08:00 having fasted overnight for 10h (except plain water). A cannula will be inserted into the antecubital vein for collection of venous blood samples. Blood pressure will be measured at 08:00 (0h) and again at hourly intervals throughout the day. Endothelial function will measured at 08:15 (0.25h) and again at 3h. At 0h, a fasting blood sample will be collected. Subsequent venous blood samples will be collected at 1.5, 1.75, 2, 3, 4, 5, 5.5, 5.75, 6, 7, 8 and 9h. Participants will consume a standardised high fat breakfast at 1h and a standardised high fat lunch at 5h. The meals consist of 57% fat, 32% carbohydrate and 11% protein. The meals provide 14.3 kcal per kg of body mass.

Participants will rest in the laboratory throughout day 2 of both the exercise and control trials.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date December 30, 2018
Est. primary completion date December 30, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- 18 to 40 year old South Asian and White European women;

- Be able to walk continuously for 1 hour;

- Weight stable for the past 3 months;

- Non-smokers;

- No known contradictions to maximal exertion exercise (e.g., recent musculoskeletal injury, congenital heart disease).

Exclusion Criteria:

- Musculoskeletal injury that has affected normal ambulation within the last month;

- Congenital heart disease;

- Any muscle or bone injuries that do not allow them to walk on a treadmill;

- Uncontrolled exercise-induced asthma;

- Coagulation or bleeding disorders;

- Diabetes (metabolism will be different to non-diabetics potentially skewing the data);

- Taking any medication that might influence fat metabolism;

- Taking any medication that might influence blood glucose (e.g., insulin for diabetes);

- Heart conditions;

- Smoking;

- Dieting or restrained eating behaviours;

- Weight fluctuation greater than 3 kg in the previous 3 months to study enrolment;

- A food allergy.

Study Design


Intervention

Behavioral:
Exercise
A 60 minute walk at 60% maximal oxygen uptake.

Locations

Country Name City State
United Kingdom National Centre for Sport and Exercise Medicine, Loughborough University Loughborough

Sponsors (2)

Lead Sponsor Collaborator
Loughborough University University Hospitals, Leicester

Country where clinical trial is conducted

United Kingdom, 

References & Publications (2)

Arjunan SP, Bishop NC, Reischak-Oliveira A, Stensel DJ. Exercise and coronary heart disease risk markers in South Asian and European men. Med Sci Sports Exerc. 2013 Jul;45(7):1261-8. doi: 10.1249/MSS.0b013e3182853ecf. — View Citation

Arjunan SP, Deighton K, Bishop NC, King J, Reischak-Oliveira A, Rogan A, Sedgwick M, Thackray AE, Webb D, Stensel DJ. The effect of prior walking on coronary heart disease risk markers in South Asian and European men. Eur J Appl Physiol. 2015 Dec;115(12):2641-51. doi: 10.1007/s00421-015-3269-7. Epub 2015 Oct 5. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Triacylglycerol Fasting on day 1 and 2. Time-course of plasma triacylglycerol concentrations in response to exercise and/or feeding on day 2. Day 1 fasting. Day 2 fasting, 1.5h, 1.75h, 2h, 3h, 4h, 5h, 5.5h, 5.75h, 6h, 7h, 8h and 9h.
Secondary Endothelial function Changes in endothelial function via flow-mediated dilatation in response to feeding and exercise. Day 1 fasting and 8.75h. Day 2 fasting and 3.5h.
Secondary Blood pressure Changes in blood pressure (systolic and diastolic). Day 1 fasting. Day 2 fasting and 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h and 9h.
Secondary Glucose Fasting on day 1 and 2. Time-course of plasma glucose concentrations in response to exercise and/or feeding on day 2. Day 1 fasting. Day 2 fasting, 1.5h, 1.75h, 2h, 3h, 4h, 5h, 5.5h, 5.75h, 6h, 7h, 8h and 9h
Secondary Total cholesterol Fasting plasma total cholesterol on day 1 and day 2 of both trials. Day 1 fasting. Day 2 fasting.
Secondary Insulin Fasting on day 1 and 2. Time-course of plasma insulin concentrations in response to exercise and/or feeding on day 2. Day 1 fasting. Day 2 fasting, 1.5h, 2h, 4h, 5h, 5.5h, 7h, 8h.
Secondary High-density lipoprotein cholesterol Fasting high-density lipoprotein cholesterol on day 1 and 2 of both trials. Day 1 fasting. Day 2 fasting.
Secondary Low-density lipoprotein cholesterol Fasting low-density lipoprotein cholesterol on day 1 and 2 of both trials. Day 1 fasting. Day 2 fasting.
Secondary Non-esterified fatty acids Fasting on day 1 and 2. Time-course of plasma non-esterified fatty acid concentrations in response to exercise and/or feeding on day 2. Day 1 fasting. Day 2 fasting, 1.5h, 2h, 4h, 5h, 5.5h, 7h and 9h.
Secondary Interleukin-6 Fasting on day 1 and 2. Time-course of plasma interleukin-6 concentrations in response to exercise and/or feeding on day 2. Day 1 fasting. Day 2 fasting, 3h, 6h and 8h.
Secondary C-Reactive protein Fasting on day 1 and 2. Time-course of plasma C-Reactive protein concentrations in response to exercise and/or feeding on day 2. Day 1 fasting. Day 2 fasting, 3h, 6h and 8h.
Secondary Peroxiredoxin-4 Fasting on day 1 and 2. Time-course of plasma peroxiredoxin-4 concentrations across day 2 of both trials. Day 1 fasting. Day 2 fasting, 3h, 6h and 8h.
Secondary Superoxide dismutase 3 Fasting on day 1 and 2. Time-course of plasma Superoxide dismutase 3 concentrations across day 2 of both trials Day 1 fasting. Day 2 fasting, 3h, 6h and 8h.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2